Working with @gacha_game_ was great for this content!You earn Abstract XP by playingYou earn points for the season 2 of Gachaand you can see the return to player is quite niceeeLoved their pack experience&& I KNOW you will toohttps://t.co/MiRudROmde <-- go here! ...

Key Highlights of SpringWorks Therapeutics - OGSIVEO (nirogacestat) is the first and only FDA-approved therapy for desmoid tumors[15] - GOMEKLI (mirdametinib) is the first and only FDA-approved therapy for both adults and children with NF1-PN[15] - SpringWorks Therapeutics expects profitability in the first half of 2026[10] - SpringWorks Therapeutics had $461.9 million in cash, cash equivalents, and marketable securities[132] OGSIVEO (Nirogacestat) for Desmoid Tumors - OGSIVEO generated $61.5 million in net revenue in Q4 2024 and $172.0 million in FY 2024[15] - Between October 2023 and October 2024, approximately 11,000 patients with desmoid tumor ICD-10 claims were identified[15] - Objective response rate (ORR) increased from 34.3% with up to 1 year of treatment to 45.7% with up to 4 years of treatment[48] GOMEKLI (Mirdametinib) for NF1-PN - GOMEKLI is approved for the treatment of adult and pediatric patients 2 years of age and older with NF1-PN[10] - The U S market includes approximately 30,000 adult and 10,000 pediatric patients with NF1-PN[15] - In clinical trials, GOMEKLI showed a confirmed overall response rate of 41% in adults (n=58) and 52% in pediatrics (n=56)[67]

For purposes of this notice, the "presentation" that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. ("Immunome") or any person on its behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. References to "we," "our," and "us" refers to Immunome and its subsidiaries. This presentation shall not cons ...

Immunome, Inc. (IMNM) shares rallied 6% in the last trading session to close at $9.3. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.1% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism regarding the company’s efforts to develop its lead pipeline candidate, varegacestat, which is currently in late-stage clinical studies for the treatment of desmoid tumors. I ...

2025年1月，Immunome完成1.5亿美元融资，此轮融资将推动核心管线的临床转化。3月，Immunome宣布靶向ROR1的ADC（抗体-偶联药物）IM-1021完 成I期临床试验首例患者给药。其核心产品管线Varegacestat（AL102）Ⅲ期RINGSIDE试验也已完成入组，预计2025年下半年公布顶线数据。 Immunome的核心竞争力是快速抗体筛选与精准递送技术。高效、精准且安全性高的治疗优势突破了传统癌症治疗中"脱靶损伤"与研发周期过长的行业瓶 颈。 这家临床阶段的靶向肿瘤学公司已累计融资5.989亿美元、21轮资本加持——成立17年的Immunome，凭什么让投资者持续买单？ 利用天然抗体解决脱靶损伤的精准性难题 传统化疗与放疗的局限性在于其作用机制缺乏特异性，药物或辐射在攻击癌细胞的同时会无差别损伤快速分裂的健康细胞（如骨髓、消化道细胞），导致 患者免疫力下降、脱发等严重副作用。这种攻击对人体健康组织损伤率高达60%。以胰腺癌为例，传统放疗虽能缩小肿瘤，但患者容易出现消化道溃疡等 严重并发症。 据塔夫茨药物开发研究中心数据，开发一款新药平均耗时10年、耗资26亿美元左右，且90%以上候选 ...

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., June 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHM ...

目前，广汽在马来西亚、泰国、印尼等国家的工厂已投入生产，未来还将打造覆盖全球各国的能源补给 网络，并携手合作伙伴构建可持续发展的绿色出行体系，促进汽车产业与社会生态协同发展。 香港市场具有重要的窗口作用和示范效应，广汽也将香港作为全球化战略的"桥头堡"和重要支点。发布 会上，广汽正式宣布启动"香港ACTION"，将从产品、渠道、服务、能源体系和出行生态方面，全面布 局香港市场。 广汽国际总经理卫海岗表示，广汽将充分发挥以广州番禺总部为中心的产业体系优势，以全产业链生态 出海的模式，将广汽打造成为香港消费者信赖的汽车品牌。 自2024年1月进入香港市场以来，广汽已在香港开设1家品牌中心、7家陈列室以及2家售后服务中心，今 年内将增设1家服务中心及1家陈列室。广汽计划2028年前在香港建成300座超充桩，同时正推动与如祺 新华财经香港6月12日电（记者李柏涛）2025国际汽车及供应链博览会12日在香港开幕，广汽集团以"科 技广汽生态出海"为主题，展出GAC、AION、HYPTEC三大产品序列8款车型，同步安排首款量产型飞 行汽车GOVY AirCab全球首发亮相、全球精品小车AION UT香港首秀。 据介绍，GO ...

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrantsTORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 434,720 shares of common stock at a purcha ...

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrantsTORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering ...

VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discovery, is pleased to announce the appointment of Paul McGuigan, P. Geo., as its Qualified Person on the exploration and development of the Radar Ti-V-Fe Property (the “Project”) in Labrador. Mr. McGuigan will advise on standards of practice for QAQC, structural mapping, drilling and deposit mode ...